HbA1c and Glucose Management Indicator Discordance Associated with Obesity and Type 2 Diabetes in Intermittent Scanning Glucose Monitoring System

被引:6
作者
Fellinger, Paul [1 ]
Rodewald, Karin [1 ]
Ferch, Moritz [1 ]
Itariu, Bianca [1 ]
Kautzky-Willer, Alexandra [1 ]
Winhofer, Yvonne [1 ]
机构
[1] Div Endocrinol & Metab, Internal Med 3, Waehringer Guertel 18-20, A-1090 Vienna, Austria
来源
BIOSENSORS-BASEL | 2022年 / 12卷 / 05期
关键词
continuous glucose monitoring; GMI; HbA1c; type; 2; diabetes; overweight; HEMOGLOBIN A1C;
D O I
10.3390/bios12050288
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Glucose management indicator (GMI) is frequently used as a substitute for HbA1c, especially when using telemedicine. Discordances between GMI and HbA1c were previously mostly reported in populations with type 1 diabetes (T1DM) using real-time CGM. Our aim was to investigate the accordance between GMI and HbA1c in patients with diabetes using intermittent scanning CGM (isCGM). In this retrospective cross-sectional study, patients with diabetes who used isCGM >70% of the time of the investigated time periods were included. GMI of four different time spans (between 14 and 30 days), covering a period of 3 months, reflected by the HbA1c, were investigated. The influence of clinical- and isCGM-derived parameters on the discordance was assessed. We included 278 patients (55% T1DM; 33% type 2 diabetes (T2DM)) with a mean HbA1c of 7.63%. The mean GMI of the four time periods was between 7.19% and 7.25%. On average, the absolute deviation between the four calculated GMIs and HbA1c ranged from 0.6% to 0.65%. The discordance was greater with increased BMI, a diagnosis of T2DM, and a greater difference between the most recent GMI and GMI assessed 8 to 10 weeks prior to HbA1c assessment. Our data shows that, especially in patients with increased BMI and T2DM, this difference is more pronounced and should therefore be considered when making therapeutic decisions.
引用
收藏
页数:9
相关论文
共 22 条
  • [1] Application of Telemedicine in Diabetes Care: The Time is Now
    Aberer, Felix
    Hochfellner, Daniel A.
    Mader, Julia K.
    [J]. DIABETES THERAPY, 2021, 12 (03) : 629 - 639
  • [2] Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
    Battelino, Tadej
    Danne, Thomas
    Bergenstal, Richard M.
    Amiel, Stephanie A.
    Beck, Roy
    Biester, Torben
    Bosi, Emanuele
    Buckingham, Bruce A.
    Cefalu, William T.
    Close, Kelly L.
    Cobelli, Claudio
    Dassau, Eyal
    DeVries, J. Hans
    Donaghue, Kim C.
    Dovc, Klemen
    Doyle, Francis J.
    Garg, Satish
    Grunberger, George
    Heller, Simon
    Heinemann, Lutz
    Hirsch, Irl B.
    Hovorka, Roman
    Jia, Weiping
    Kordonouri, Olga
    Kovatchev, Boris
    Kowalski, Aaron
    Laffel, Lori
    Levine, Brian
    Mayorov, Alexander
    Mathieu, Chantal
    Murphy, Helen R.
    Nimri, Revital
    Norgaard, Kirsten
    Parkin, Christopher G.
    Renard, Eric
    Rodbard, David
    Saboo, Banshi
    Schatz, Desmond
    Stoner, Keaton
    Urakami, Tatsuiko
    Weinzimer, Stuart A.
    Phillip, Moshe
    [J]. DIABETES CARE, 2019, 42 (08) : 1593 - 1603
  • [3] The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading
    Beck, Roy W.
    Connor, Crystal G.
    Mullen, Deborah M.
    Wesley, David M.
    Bergenstal, Richard M.
    [J]. DIABETES CARE, 2017, 40 (08) : 994 - 999
  • [4] Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring
    Bergenstal, Richard M.
    Beck, Roy W.
    Close, Kelly L.
    Grunberger, George
    Sacks, David B.
    Kowalski, Aaron
    Brown, Adam S.
    Heinemann, Lutz
    Aleppo, Grazia
    Ryan, Donna B.
    Riddlesworth, Tonya D.
    Cefalu, William T.
    [J]. DIABETES CARE, 2018, 41 (11) : 2275 - 2280
  • [5] Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c
    Cohen, Robert M.
    Franco, Robert S.
    Khera, Paramjit K.
    Smith, Eric P.
    Lindsell, Christopher J.
    Ciraolo, Peter J.
    Palascak, Mary B.
    Joiner, Clinton H.
    [J]. BLOOD, 2008, 112 (10) : 4284 - 4291
  • [6] Continuous Glucose Monitoring Devices: Past, Present, and Future Focus on the History and Evolution of Technological Innovation
    Didyuk, Olesya
    Econom, Nicolas
    Guardia, Angelica
    Livingston, Kelsey
    Klueh, Ulrike
    [J]. JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2021, 15 (03): : 676 - 683
  • [7] Measurement Performance of Two Continuous Tissue Glucose Monitoring Systems Intended for Replacement of Blood Glucose Monitoring
    Freckmann, Guido
    Link, Manuela
    Pleus, Stefan
    Westhoff, Antje
    Kamecke, Ulrike
    Haug, Cornelia
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 (08) : 541 - 549
  • [8] Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin
    Gomez-Peralta, Fernando
    Choudhary, Pratik
    Cosson, Emmanuel
    Irace, Concetta
    Rami-Merhar, Birgit
    Seibold, Alexander
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (04) : 599 - 608
  • [9] Glucose Management Indicator Based on Sensor Data and Laboratory HbA1cin People With Type 1 Diabetes From the DPV Database: Differences by Sensor Type
    Grimsmann, Julia M.
    von Sengbusch, Simone
    Freff, Markus
    Ermer, Uwe
    Placzek, Kerstin
    Danne, Thomas
    Hammer, Elke
    Holl, Reinhard W.
    [J]. DIABETES CARE, 2020, 43 (09) : E111 - E112
  • [10] Glycemic Metrics Derived From Intermittently Scanned Continuous Glucose Monitoring
    Hansen, Klavs Wurgler
    Bibby, Bo Martin
    [J]. JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2022, 16 (01): : 113 - 119